Works matching IS 11745886 AND DT 2024 AND VI 24 AND IP 4
Results: 7
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Pop PK and PK/PD Analyses of Pegcetacoplan in PNH: R. L. Crass et al.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 563, doi. 10.1007/s40268-024-00500-7
- By:
- Publication type:
- Article
Acknowledgement to Referees: Acknowledgement to Referees: Acknowledgement to Referees.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 501, doi. 10.1007/s40268-024-00498-y
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics of a Lyophilized Formulation of Rusfertide: N. B. Modi et al
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 539, doi. 10.1007/s40268-024-00497-z
- By:
- Publication type:
- Article
In-Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions: Stability of Sandoz Rituximab Biosimilar at Prolonged Room Temperature Conditions: R. Borišek et al
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 553, doi. 10.1007/s40268-024-00496-0
- By:
- Publication type:
- Article
Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study: Bioequivalence Analysis of Ondansetron Hydrochloride Tablets: C. Jia et al.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 531, doi. 10.1007/s40268-024-00493-3
- By:
- Publication type:
- Article
Pharmacokinetics and Bioequivalence of Two Powders of Azithromycin for Suspension: A Nonblinded, Single-Dose, Randomized, Three-Way Crossover Study in Fed and Fasting States Among Healthy Chinese Volunteers: Pharmacokinetics and Bioequivalence of Two Powders of Azithromycin: J. Shao et al
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 517, doi. 10.1007/s40268-024-00492-4
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants: Efgartigimod in Healthy Chinese Participants: S. Jing et al.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 4, p. 505, doi. 10.1007/s40268-024-00490-6
- By:
- Publication type:
- Article